FLT3 and acute myeloid leukemia: Gilteritinib is a TKI that suppresses the growth of AML cells by inhibiting FLT3 and its downstream phosphorylation in patients with Internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutations [2].